drugset / Trial / NCT07175506
Study of CM559 in Healthy Subjects
RandomizedSequentialQuadruple-blindTreatment
Summary
This study is a single center, randomized, double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM559 administered intravenously at different doses in healthy male subjects.
Timeline
- Start
- 2025-09
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM559 | Unknown | — | Intravenous |
Indications
No indication recorded.